The reorganization comes as the company shifts its focus toward the completion of the LOTIS-5 and LOTIS-7 trials. By reducing staff, ADC Therapeutics expects to capture annualized savings of approximately $10 million, though the move will incur one-time pre-tax charges of $3 million in the second quarter of 2026. CEO Ameet Mallik stated that the restructuring is designed to increase financial flexibility as the firm prepares for an August 2026 pre-sBLA meeting with the FDA.

The regulatory roadmap remains a primary driver for the company’s current strategy. Following data from the Phase 3 LOTIS-5 trial, ADC Therapeutics intends to submit a supplemental Biologics License Application (sBLA) in the fourth quarter of 2026 for ZYNLONTA’s use in combination with rituximab for relapsed or refractory diffuse large B-cell lymphoma. Simultaneously, the company is advancing the Phase 1b LOTIS-7 trial, with data expected by year-end 2026, while continuing to support investigator-initiated trials for indolent lymphomas.